Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Chipotle Mexican Grill, Inc. (CMG) vs Sanofi SA (SNY) Price & Performance

Chipotle Mexican Grill, Inc.Trade

Price performance (Past 24H)

Key statistics

Chipotle Mexican Grill, Inc. vs Sanofi SA — how do they compare? Chipotle Mexican Grill, Inc. trades at $32.64 (market cap $40.49B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 2.6× Chipotle Mexican Grill, Inc.'s market cap, and Sanofi SA pays a 5.55% dividend while Chipotle Mexican Grill, Inc. pays none. Which is the better fit depends on your goals.

CMGSNY
Market Cap
$40.49B$104.30B
Sector
Consumer CyclicalHealth
52-Week High
$44.04$52.34
52-Week Low
$28.17$41.33
Enterprise Value
$45.24B$124.19B
Dividend Yield
5.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Chipotle Mexican Grill, Inc.

CMG trades at $32.71, up 1.76% on the day, with a bearish technical signal driven by moving averages. The company reported strong revenue growth to $11.93B in 2025 and has consistently beaten EPS estimates in recent quarters. However, net cash flow turned negative at -$392M due to aggressive financing activities. Recent news highlights a salmonella outbreak linked to jalapeños, creating near-term headwinds.

Wall Street maintains a bullish stance with a $42.17 consensus price target, representing 29% upside, and no sell ratings. Key risks include food safety issues, margin compression, and negative cash flow. The stock's high P/E of 29.63 requires sustained earnings growth to justify valuation.

Sanofi SA

SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.

Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Chipotle Mexican Grill, Inc.

Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.

Read more on CMG

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY